Volume 15, Number 7—July 2009
Reactivation of Bovine Tuberculosis in Patient Treated with Infliximab, Switzerland
To the Editor: Increased risk for reactivation of tuberculosis (TB) after treatment with tumor necrosis factor (TNF) antagonists, particularly infliximab, is well documented (1). We describe a case of peritoneal TB, probably resulting from reactivation of Mycobacterium bovis infection after infliximab treatment. In retrospect, reactivation might have been preventable had physicians been aware of the patient’s history of regularly drinking fresh cow’s milk from a local farm in Switzerland during 1944–45, when bovine TB was prevalent.
The patient was a 69-year-old Swiss woman who was examined for weakness, abdominal pain, increasing abdominal girth, and weight loss in April 2008. Her history included a diagnosis of Crohn disease in 1978 and treatment with glucocorticoids, cyclosporine, and mercaptopurine. In November 2007, during a recurrence of Crohn disease and while receiving treatment with azathioprine, the patient had a negative interferon gamma release assay (IGRA) result (QuantiFERON-TB in Tube test; Cellestis International, Carnegie, Victoria, Australia) and an unremarkable chest radiograph. On November 30, 2007, she was given prednisone (40 mg/d for 2 weeks, then tapered) and prescribed 3 doses of infliximab because of severe inflammation seen during colonoscopy (5 mg/kg on November 30, 2007, January 4, 2008, and February 15, 2008). She was hospitalized on April 25, 2008, at which time she had ascites; the fluid contained 1.4 × 109/L leukocytes (79.5% lymphocytes) but was negative for acid-fast bacilli on direct examination and PCR testing for Mycobacterium tuberculosis complex. Laparoscopy on May 2, 2008, showed extensive peritoneal inflammation. Peritoneal biopsy samples contained acid-fast bacilli and caseating granulomas; PCR for M. tuberculosis complex was positive. At this time, results of a repeat QuantiFERON-TB in Tube test and a tuberculin skin test (TST) were negative, but a T-SPOT.TB (Oxford Immunotec, Abingdon, UK) test was positive (6-kDa early secretory antigenic target [ESAT-6], >20 spots; 10-kDa culture filtrate protein [CFP-10], 11 spots). M. bovis ssp. bovis was grown in cultures of peritoneal biopsy samples. For culture, the MGIT 960 automated culture system (Becton Dickinson, Sparks, MD, USA) was used. The isolate was identified by use of a multiplex PCR-based, solid-phase, reverse-hybridization assay (GenoType MTBC, Hain Lifescience GmbH, Nehren, Germany), excluding M. bovis BCG (2). The patient was discharged May 30, 2008. In January 2009, she was much improved after treatment with isoniazid/rifampin/ethambutol for 3 months and moxifloxacin/rifampin for 5 months.
This case of presumed reactivation of peritoneal TB caused by M. bovis in a patient treated with infliximab highlights the need to be aware of local epidemiology with regard to transmissible infectious diseases. It particularly emphasizes the value of careful history taking regarding consumption of unpasteurized dairy products in assessing risk for latent TB infection (LTBI) before starting anti-TNF treatment. Some infectious diseases experts (3) recommend considering LTBI treatment before prescribing anti-TNF therapy even when TST is negative or only minimally positive (<5 mm induration) for patients with epidemiologic or clinical hints of LTBI. This case indicates that this recommendation should be extended to assessment of the probability of latent M. bovis infection. This decision may not be easy, and referral to a TB specialist should be considered. Excluding LTBI on the basis of a negative TST result or IGRA is problematic because of the limited sensitivity of these tests, especially for immunosuppressed patients (4). Of note, the antigens used in IGRAs are present in M. bovis. Discordant TST and IGRA results are frequent, and these differences are not easily explained (4). However, IGRAs are not confounded by prior vaccination with M. bovis BCG, and the T-SPOT.TB test may have a higher sensitivity than QuantiFERON-TB and QuantiFERON-TB Gold tests (Cellestis International) (5,6). Our patient had a positive T-SPOT.TB result and negative QuantiFERON-TB and TST results at the time of her diagnosis of peritoneal TB.
Recently, another case of peritoneal TB due to M. bovis in a patient treated with infliximab was reported in Denmark. This patient’s exposure presumably consisted of consumption of unpasteurized milk at a dairy (7). Tuberculosis cases caused by M. bovis are probably underreported because many laboratories determine only whether a pathogen belongs to M. tuberculosis complex. In the United States, genotyping of culture-confirmed M. tuberculosis complex has been routinely done only since 2004 (8).
Our patient probably acquired M. bovis infection by frequent consumption of unpasteurized milk in a rural area of Switzerland during the 1940s. Infection by the respiratory route is conceivable but unlikely. As the patient traveled rarely, and only in industrialized countries, more recent transmission of M. bovis seems unlikely. According to the requirements of section 18.104.22.168 of the World Organisation for Animal Health International Animal Health Code, Switzerland has officially been free from bovine TB since 1959. The last sporadic case occurred in 2003, although eradication has not been achieved in all neighboring European countries (9). Of note, in the United States and Canada, where M. bovis has been virtually eliminated in cattle (10), M. bovis infection continues to be diagnosed today, particularly in children of Hispanic origin and those born outside the United States. The principal infection route may be consumption of unpasteurized dairy products from Mexico (8). Awareness of the epidemiology of bovine TB and careful history taking regarding recent or distant (in countries where M. bovis infection in cattle has been eradicated) consumption of unpasteurized dairy products may prompt preventive chemotherapy before the start of anti-TNF treatment. Thus, a potentially increasing number of human TB cases due to M. bovis may be prevented.
- Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11.
- Somoskovi A, Dormandy J, Rivenburg J, Pedrosa M, McBride M, Salfinger M. Direct comparison of the genotype MTBC and genomic deletion assays in terms of ability to distinguish between members of the Mycobacterium tuberculosis complex in clinical isolates and in clinical specimens. J Clin Microbiol. 2008;46:1854–7.
- Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–6.
- Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.
- Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131:1898–906.
- Pai M, Zwerling A, Menzies D. Systematic review: T-cell–based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.
- Larsen MV, Sorensen IJ, Thomsen VO, Ravn P. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J. 2008;32:229–31.
- Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP, Human tuberculosis due to Mycobacterium bovis in the United States, 1995–2005. Clin Infect Dis. 2008;47:168–75.
- Reviriego Gordejo FJ, Vermeersch JP. Towards eradication of bovine tuberculosis in the European Union. Vet Microbiol. 2006;112:101–9.
- Gilsdorf MJ, Ebel ED, Disney TW. Benefit and cost assessment of the U.S. bovine tuberculosis eradication program. In: Thoen CO, Steele JH, Gilsdorf MJ, editors. Mycobacterium bovis infections in animals and humans. 2nd ed. Ames (IA): Blackwell Publishing; 2006. p. 89–99.
Suggested citation for this article: Nager M, Tarr PE, Haack HG, Martius F, Stoebe C, Frei R, et al. Reactivation of bovine tuberculosis in patient treated with infliximab, Switzerland [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jul [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/7/09-0024
Please use the form below to submit correspondence to the authors or contact them at the following address:
Andreas W. Jehle, Department of Medicine, Kantonsspital Bruderholz, University of Basel, CH-4101 Bruderholz, Switzerland
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 09, 2010
- Page last updated: November 09, 2010
- Page last reviewed: November 09, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)